Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory disease involving the synovial joints, where bone and cartilage erosion lead to irreversible joint damage. This disease affects 18 million people worldwide, and nearly three times as many women as men. RA occurs when the immune system loses its normal state of balanced control and activates sustained inflammation in the soft inner lining of joints, called synovial tissue. This inflammation produces joint pain, swelling, and stiffness, and can lead to permanent damage and deformity in structural joint elements like cartilage and bone. Significantly reduced physical function typically accompanies these features.
Rheumatoid arthritis disease affects 18 million people worldwide.”
J&J’s approach to Rheumatoid arthritis (RA)
Unmet patient needs continue to exist for additional treatment options for patients that are resistant to current therapies. Johnson & Johnson is committed to addressing unmet needs for people living with RA. We are evaluating an investigational products a potential treatment for patients with moderate to severe RA, who are not experiencing remission.
Keeping patients at the center of everything we do, Johnson & Johnson is committed to tirelessly pushing the boundaries of science to deliver innovative and transformational approaches for autoantibody-driven diseases, building on the ever-evolving understanding of the immune system.
New discoveries into how the immune system functions are leading to profound learnings about drivers of disease, helping us to more rapidly and effectively expand the development of medicines.
